The AlphaBet trial
@PeterMacCC @TheLancetOncol release today
@myESMO #ESMO25: combining Lu-177 PSMA-I&T Ra-223 in men with metastatic castration-resistant
#ProstateCancer is safe, feasible, and active.
✅ No dose-limiting toxicities
💪 PSA-50% decline in 55%
🧬 Supports future α β theranostic combos.
🔗
authors.elsevier.com/a/1lyc6…
Congrats
@LouiseKostos: what an amazing PhD!
Thank-you to
@PCF_Science @pros_tic @Bayer for funding & support, co-senior author
@AzadOncology, all the co-authors, wider village of contributors and most importantly our patients and their families for participating.